KALA BIO, Inc.

As of June 30, 2026, KALA BIO, Inc. carries a market capitalization of 33.07M, placing it among publicly traded companies globally. Its enterprise value stands at 25.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

KALA BIO, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, KALA BIO, Inc. has 19.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, KALA BIO, Inc. maintains a current ratio of 6.88, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -43.23, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 14.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, KALA BIO, Inc.'s stock has declined approximately 99.57% over the past 52 weeks. The 50-day moving average sits at 0.54, while the 200-day moving average is 8.43.

Over the twelve months ended June 30, 2026, KALA BIO, Inc. generated - - in revenue and converted that into -10.08M in net income, yielding earnings per share of -3.19. EBITDA reached -20.80M, while operating income came in at -23.93M.

These figures are as of June 30, 2026. Total book value stands at 9.04M, with working capital of 9.04M providing operational flexibility.

KALA BIO, Inc. produced -19.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting 1,000.00 in capital expenditures, free cash flow totaled -19.86M - equivalent to -6.28 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -367.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 14.67, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KALA BIO, Inc. shareholders.

KALA BIO, Inc.'s most recent stock split took place on May 12, 2026 with a 50:1 split ratio.

As of June 30, 2026, KALA BIO, Inc. has an Altman Z-Score of -85.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.